Nanoliposomes as nonviral vectors in cancer gene therapy.

Autor: Yildiz SN; Department of Biomedical Engineering Erciyes University Kayseri Turkey., Entezari M; Department of Genetics Faculty of Advanced Science and Technology Tehran Medical Sciences Islamic Azad University Tehran Iran.; Department of Medical Convergence Sciences Farhikhtegan Hospital Tehran Medical Sciences Islamic Azad University Tehran Iran., Paskeh MDA; Department of Genetics Faculty of Advanced Science and Technology Tehran Medical Sciences Islamic Azad University Tehran Iran.; Department of Medical Convergence Sciences Farhikhtegan Hospital Tehran Medical Sciences Islamic Azad University Tehran Iran., Mirzaei S; Department of Biology Faculty of Science Islamic Azad University Science and Research Branch Tehran Iran., Kalbasi A; Department of Pharmacy Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA., Zabolian A; Department of Orthopedics Shahid Beheshti University of Medical Sciences Tehran Iran., Hashemi F; Department of Comparative Biosciences Faculty of Veterinary Medicine University of Tehran Tehran Iran., Hushmandi K; Department of Clinical Sciences Institute Nephrology and Urology Research Center Baqiyatallah University of Medical Sciences Tehran Iran., Hashemi M; Department of Genetics Faculty of Advanced Science and Technology Tehran Medical Sciences Islamic Azad University Tehran Iran.; Department of Medical Convergence Sciences Farhikhtegan Hospital Tehran Medical Sciences Islamic Azad University Tehran Iran., Raei M; Department of Epidemiology and Biostatistics School of Health Baqiyatallah University of Medical Sciences Tehran Iran., Goharrizi MASB; Department of Biotechnology College of Science, University of Tehran Tehran Iran., Aref AR; Belfer Center for Applied Cancer Science Dana-Farber Cancer Institute Harvard Medical School Boston Massachusetts USA.; Department of Translational Sciences Xsphera Biosciences Inc. Boston Massachusetts USA., Zarrabi A; Department of Biomedical Engineering Faculty of Engineering and Natural Sciences Istinye University Istanbul Turkey., Ren J; Shanghai Institute of Cardiovascular Diseases Department of Cardiology Zhongshan Hospital Fudan University Shanghai China., Orive G; NanoBioCel Research Group School of Pharmacy University of the Basque Country (UPV/EHU) Vitoria-Gasteiz Spain.; University Institute for Regenerative Medicine and Oral Implantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua) Vitoria-Gasteiz Spain.; Bioaraba, NanoBioCel Research Group Vitoria-Gasteiz Spain.; The Academia Singapore Eye Research Institute Singapore Singapore., Rabiee N; Centre for Molecular Medicine and Innovative Therapeutics Murdoch University Perth Western Australia Australia., Ertas YN; Department of Biomedical Engineering Erciyes University Kayseri Turkey.; ERNAM-Nanotechnology Research and Application Center Erciyes University Kayseri Turkey.; UNAM-National Nanotechnology Research Center Bilkent University Ankara Turkey.
Jazyk: angličtina
Zdroj: MedComm [MedComm (2020)] 2024 Jun 25; Vol. 5 (7), pp. e583. Date of Electronic Publication: 2024 Jun 25 (Print Publication: 2024).
DOI: 10.1002/mco2.583
Abstrakt: Nonviral vectors, such as liposomes, offer potential for targeted gene delivery in cancer therapy. Liposomes, composed of phospholipid vesicles, have demonstrated efficacy as nanocarriers for genetic tools, addressing the limitations of off-targeting and degradation commonly associated with traditional gene therapy approaches. Due to their biocompatibility, stability, and tunable physicochemical properties, they offer potential in overcoming the challenges associated with gene therapy, such as low transfection efficiency and poor stability in biological fluids. Despite these advancements, there remains a gap in understanding the optimal utilization of nanoliposomes for enhanced gene delivery in cancer treatment. This review delves into the present state of nanoliposomes as carriers for genetic tools in cancer therapy, sheds light on their potential to safeguard genetic payloads and facilitate cell internalization alongside the evolution of smart nanocarriers for targeted delivery. The challenges linked to their biocompatibility and the factors that restrict their effectiveness in gene delivery are also discussed along with exploring the potential of nanoliposomes in cancer gene therapy strategies by analyzing recent advancements and offering future directions.
Competing Interests: Author Amir Reza Aref is an employee of Xsphera Biosciences, Inc. Author Gorka Orive is an employee of Bioaraba, NanoBioCel Research Group. Other authors have no interest to declare.
(© 2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz: